Literature DB >> 25390496

Adherence to secondary prevention therapies in acute coronary syndrome.

Jay B Thakkar1, Clara K Chow2.   

Abstract

Despite overwhelming evidence of the effectiveness of secondary prevention therapies, surveys indicate poor adherence to medical treatments and lifestyle recommendations after an acute coronary syndrome. The term adherence is preferred over compliance, as the former suggests a therapeutic alliance, whereas the latter reflects passive patient obedience. Poor adherence results from a complex interplay of multiple factors at patient, practitioner and system levels. Poor adherence among patients with stable coronary artery disease is associated with increased risk of cardiovascular admissions (10%-40%), coronary interventions (10%-30%) and cardiovascular mortality (50%-80%). Improving adherence is a complex process. A range of interventions that target modifiable factors influencing adherence have been explored, but there are no guidelines to guide the choice, and multidisciplinary efforts may be needed. Future research in the area should focus on comparative efficacy of interventions to enhance adherence.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25390496     DOI: 10.5694/mja14.01157

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  2 in total

1.  Application of a risk-guided strategy to secondary prevention of coronary heart disease: analysis from a state-wide data linkage in Queensland, Australia.

Authors:  Quan L Huynh; Son Nghiem; Joshua Byrnes; Paul A Scuffham; Thomas Marwick
Journal:  BMJ Open       Date:  2022-05-04       Impact factor: 2.692

2.  Blood pressure target achievement and antihypertensive medication use in women and men after first-ever myocardial infarction: the Tromsø Study 1994-2016.

Authors:  Laila A Hopstock; Anne Elise Eggen; Maja-Lisa Løchen; Ellisiv B Mathiesen; Amalie Nilsen; Inger Njølstad; Tom Wilsgaard
Journal:  Open Heart       Date:  2018-01-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.